The Old Meets the New: Efficacy and Mechanisms of Biophotonic Therapies in Viral and Microbial Illness

The present Brief Communication is based on retrospective analysis and review of patient outcomes using biophotonics and bioelecrromagnetic therapies as a primary treatment regimen for patients with confirmed HIV, antimicrobial resistant Staphylococcus aureus, and other infectious illness. A member of the Coronaviridiae family, the recently discovered coronavirus SARS-COV-2 is well known to cause respiratory, gastrointestinal, and other illnesses in both humans and animals. It has been linked to the COVID-19 illness.1,2 The coronavirus strain that causes Covid-19 is also genetically related to some zoonotic viruses isolated from pangolin, bats, and camels that have previously caused respiratory illness in humans, even though the SARS-COV-2 viral strain's precise origin or source has not yet been determined. Thus, theoretically the human infections likely could have occurred from an intermediate animal host via incidental interspecies transmission or other unconfirmed epidemiological origins as is believed to have occurred with the MERS strain. Prior to January 2020, the coronavirus Sars 2-Cov-19 pandemic first appeared in Wuhan, China, and then rapidly spread throughout the world from spring to fall of that same year.2 Millions of people were affected worldwide by the newly identified virus by year's end, and the infection has persisted through the present day. During this time, several infectious COVID-19 mutations have evolved, some of which have a higher potential for infection than the original virus. There have been ongoing outbreaks of the viral mutants, which frequently appear to bypass earlier variants and immunities developed through vaccinations. These treatment modalities have been utilized successfully for many years both for the treatment of infectious illnesses and for the decontamination of PPE and other patient-connected applications, prior to the development of antimicrobial and antiviral pharmaceutic agents as the current standard of care in common present-day therapies for infectious diseases. Several previously undefined therapeutic benefits of sunlight exposure have been practiced in many cultures for thousands of years, long before the discovery of the photon and introduction of countless newly discovered molecular biological approaches in the treatment of human illness and disease, and with the contributions of modern therapeutic approaches are likely to continue well into the next millennia.